[go: up one dir, main page]

WO2009030302A1 - Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives - Google Patents

Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives Download PDF

Info

Publication number
WO2009030302A1
WO2009030302A1 PCT/EP2008/005614 EP2008005614W WO2009030302A1 WO 2009030302 A1 WO2009030302 A1 WO 2009030302A1 EP 2008005614 W EP2008005614 W EP 2008005614W WO 2009030302 A1 WO2009030302 A1 WO 2009030302A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
dihydroxyacetone
preparations
cosmetic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/005614
Other languages
German (de)
English (en)
Inventor
Rainer Wolber
Christoph Smuda
Cathrin Scherner
Michael WÖHRMANN
Sabrina Ahlheit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of WO2009030302A1 publication Critical patent/WO2009030302A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to active ingredient combinations, in particular those for tanning the human skin, as well as cosmetic and dermatological preparations containing such drug combinations.
  • UVC region The damaging effect of the ultraviolet part of solar radiation on the skin is well known. While rays having a wavelength smaller than 290 nm (the so-called UVC region) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB region, cause erythema simple sunburn or even more or less severe burns.
  • UVA range it is important to have filter substances available, since its rays can cause damage. It has been proven that UVA radiation leads to damage of the elastic and collagenous fibers of the connective tissue, which causes the skin to age prematurely, and that it is the cause of numerous phototoxic and photoallergic shear reactions can be seen. The damaging influence of UVB radiation can be amplified by UVA radiation.
  • UVA radiation can also cause skin damage by damaging the skin's own keratin or elastin. This reduces the elasticity and water retention capacity of the skin, i. The skin becomes less supple and tends to wrinkle.
  • the strikingly high prevalence of skin cancer in areas of strong sunlight indicates that damage to the genetic information in the cells is evidently also caused by sunlight, especially UV-A radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism.
  • such photochemical reaction products are radic compounds, e.g. Hydroxyl radicals.
  • Undefined radical photoproducts which are formed in the skin itself, can also show uncontrolled sequelae due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule, can also be seen on UV irradiation, as can short-lived epoxides and many others.
  • Singlet oxygen for example, is distinguished from the normally present triplet oxygen (radical ground state) by increased reactivity. However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation counts as ionizing radiation. There is thus the risk that ionic species may also be formed on exposure to UV radiation, which in turn may intervene oxidatively in the biochemical processes.
  • the pigmentation of human skin is essentially caused by the presence of melanin.
  • Melanin and its breakdown products (melanoids), carotene, degree of haemorrhage and the nature and thickness of the stratum corneum and other skin layers make skin shades different from virtually white (with reduced filling or in the absence of blood vessels) or yellowish to light brown-reddish, bluish to brown Nuances and finally appear almost black.
  • the individual skin regions show different depth of color due to different amounts of melanin. According to recent findings, the distribution of melanin in the skin has At least as much influence on the color appearance (browning) as the amount of melanin.
  • the natural melanin protects the skin from penetrating UV radiation.
  • melanin With strong pigmentation (for example, in colored people, but also in fair-skinned persons after some UV irradiation), melanin is also found in the stratum spinosum and even in the stratum corneum. It weakens the UV radiation by up to approx. 90% before it reaches the corium.
  • Skin type I never tans, always gets a sunburn.
  • Skin type II hardly tans, easily gets sunburned.
  • Skin type III tans well on average.
  • Skin type IV tans easily and persistently, almost never gets sunburned.
  • Skin type V Dark, often almost black, skin never gets sunburned.
  • Carotene is stored in the subcutaneous adipose tissue by regular intake of carotene preparations, the skin gradually turns orange to yellow-brown.
  • a slight skin tone can be achieved (eg extracts of fresh green walnut shells, henna)
  • the staining can also be done by way of chemical modification of the skin's hom für with so-called self-tanning preparations.
  • the most important active ingredient is dihydroxyacetone (DHA).
  • DHA dihydroxyacetone
  • Dihydroxyacetone can be referred to as ketotriose and reacts as reducing sugar with the amino acids of the skin or the free amino and imino groups of keratin via a series of intermediates in the sense of a Maillard reaction to brown-colored substances, so-called melanoids, which occasionally melanoidins to be named.
  • the glycyrrhetinic acid isolable from licorice is the aglycone of glycyrrhizin (which is the 2 ⁇ -glucuronido- ⁇ -glucuronide of glycyrrhetinic acid).
  • Glycyrrhizin is characterized by the following structure:
  • Glycyrrhetinic acid is used as an anti-inflammatory agent.
  • Glycyrrhizinic acid 3-hemisuccinate serves as an anticoagulant.
  • Glycyrrhizin has an anti-inflammatory effect and is used in the form of liquorice juice (Sirupus Iquiritiae) as a cough suppressant and expectorant.
  • Glycyrrhetinic acid and glycyrrhizin are known to the person skilled in the art as active ingredients having a skin-lightening activity.
  • glycyrrhetinic acid is preferred according to the invention for glycyrrhizin, but it may also be advantageously replaced by it partially or completely.
  • the weight ratios of glycyrrhetinic acid and / or glycyrrhizin on the one hand and dihydroxyacetone on the other hand are selected from the range from 10: 1 to 1: 100 in the active substance combinations or preparations.
  • Particularly preferred weight ratios of glycyrrhetinic acid and / or glycyrrhizin on the one hand and dihydroxyacetone on the other hand in the active substance combinations or the preparations containing them are from the range from 1: 30 to 1: 7.5, very particularly preferably from the range of 1:20 and 1: 10 selected.
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.001-10% by weight of glycyrrhetinic acid and / or glycyrrhizin, particularly preferably 0.01-1% by weight and very particularly preferably 0.05-0.25% by weight.
  • cosmetic or dermatological preparations according to the invention preferably contain 0.1-3% by weight of dihydroxyacetone.
  • cosmetic or dermatological preparations according to the invention advantageously contain 0.1-3% by weight of erythrulose.
  • a preferred embodiment of the present invention relates to preparations containing 0.001-10% by weight of glycyrrhetinic acid and / or glycyrrhizin and 0.1-3% by weight of erythrulose and / or 0.1-3% of dihydroxyacetone.
  • Preferred ratios of glycyrrhetinic acid and erythrulose are between 10: 1 to 1: 100, more preferably between 1: 30 and 1: 7.5, most preferably between 1:20 and 1:10.
  • Cosmetic or dermatological preparations according to the invention particularly preferably contain 0.01-1% by weight of glycyrrhetinic acid and / or glycyrrhizin and 0.5-2% by weight of erythrulose and / or dihydroxyacetone, a combination of erythrulose and dihydroxyacetone in the ratio 1: 5 to 5: 1, based on the total composition of the preparations.
  • cosmetic or dermatological preparations containing 0.05 to 0.25% by weight of glycyrrhetinic acid and 0.75 to 1.75% by weight of dihydroxyacetone, based on the total composition of the preparations.
  • the formulations of the invention showed that a) the skin barrier is strengthened b) skin moisture is increased c) in particular unwanted pigmentation disorders such as melasma, various forms of post-inflammatory hyperpigmentation due to, for example, scars or sunburns, Age spots, freckles, liver spots, vitiligo, etc. are alleviated or eliminated. d) skin wrinkles are reduced.
  • preparations according to the invention surprisingly also led to an improvement of the contours of the skin and to an increased elasticity, in particular on the weak connective tissue areas of the body, such as e.g. on the legs, stomach and buttocks.
  • These skin-firming and firming effects are accompanied by an improvement of the cell metabolism with the reduction of the orange peel, so for example with the reduction of skin dents on the thigh area ("riding pants").
  • Emulsions according to the invention for the purposes of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fatty substances, as well as water and one or more emulsifiers, as they are commonly used for such a type of formulation.
  • Medicinal topical compositions according to the present invention usually contain one or more drugs in effective concentration.
  • drugs for the sake of simplicity, reference is made to the clear distinction between cosmetic and medical use and corresponding products to the statutory provisions of the Federal Republic of Germany (for example, Cosmetics Regulation, Food and Medicines Act).
  • the cosmetic and / or dermatological formulations according to the invention may be composed as usual and used for the treatment of the skin and / or the hair in the sense of a dermatological treatment or a treatment in the sense of nourishing cosmetics. But they can also be used in make-up products in decorative cosmetics or in the cosmetic and dermatological cleaning products.
  • the moire (s) selected from the group are glycerol, lactic acid and / or lactates, in particular sodium lactate, butylene glycol, propylene glycol, biosaccharide gum-1, glycine soya, ethylhexyloxyglycerol, pyrrolidonecarboxylic acid and urea ,
  • polymeric moisturizers from the group of water-soluble, water-swellable or water-soluble polysaccharides.
  • hyaluronic acid, chitosan and a fucose-rich polysaccharide which are filed in the Chemical Abstracts under the registration number 178463-23-5 and z.
  • glycerol as a moisturizer, preferably in a concentration of 0.05 to 30 wt .-%, particularly preferably 1 to 10 wt .-%, each based on the total weight of the preparation.
  • the solvents used can be: water or aqueous solutions, furthermore oils, such as Triglycerides of capric or caprylic acid, but preferably castor oil, fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty acids with alcohols of low C number, for example with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with lower alkanoic acids Number or with fatty acids, but also alcohols, diols or polyols low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl - or - monoethyl ether and analogous products.
  • oils such as Triglycerides of capric or caprylic acid, but preferably cast
  • mixtures of the abovementioned solvents are used, as may be an advantageous further constituent of alcohol in the case of alcoholic solvents.
  • Cosmetic and dermatological preparations according to the invention may be in various forms, such as e.g. Usually be used for this type of preparations. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water (W / O / W), oil-in-water-in-oil (O / W / O), a gel, a hydrodispersion, a lamellar phase, a liquid isotropic solution phase, a micellar phase, a solid or dispersed one. or hexagonal phase, a solid or dispersed single or multiple cubic phase, an isotropic phase, a crystalline phase, a solid stick or even an aerosol.
  • W / O water-in-oil
  • O / W oil-in-water
  • O oil-in-water-in-oil
  • a gel
  • the active compounds according to the invention can also be used with particular advantage in microemulsions, for example as described in German Offenlegungsschrift DE-195 9 079.
  • the oil phase of the preparations according to the invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2 Hexyldecyl stearate, 2-octyl dodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, Erucylerucat and synthetic, semi-synthetic and natural mixtures of such esters, eg jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, in particular triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12-18, carbon atoms.
  • the fatty acid triglycerides can be advantageously selected from the group of synthetic, semi-synthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.
  • the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12 . 15- alkyl benzoate, caprylic-capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12 . 15- alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12 . 15- Alkylbenzoat and Isotridecylisononanoat and mixtures of C 12-15 - alkyl benzoate, 2-Ethylhexylisostearat and Isotridecylisononanoat.
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention.
  • the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or silicone oils.
  • cyclomethicone (octamethylcyclotetrasiloxane) is used as the silicone oil to be used according to the invention.
  • other silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • mixtures of cyclomethicone and isotridecyl isononanoate, of cyclomethicone and 2-ethylhexyl isostearate are particularly advantageous.
  • the content of the oil phase is between 1 and 50 wt .-%, based on the total weight of the preparations, preferably 2.5 to 30 wt .-%, particularly preferably 5 to 15 wt .-%.
  • the cosmetic and / or dermatological formulations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatological agents.
  • active ingredients to be used in the context of the present invention are those which improve the condition of the skin, in particular active ingredients for the treatment and / or care of aging skin, for example those which reduce the development of wrinkles or even existing wrinkles.
  • biochinones in particular ubiquinone (Q10), folic acid and its derivatives (in particular tetrahydrofolic acid and dihydrofolic acid), niacin and its derivatives (in particular niacinamide), creatine and creatinine, carnitine, biotin, isoflavone, hop and hops malt extracts ,
  • agents that promote the restructuring of connective tissue such as natural and synthetic isoflavonoids and isoflavonoid-containing plant extracts - such.
  • soy and clover extracts - can be used very well in the formulations of the invention.
  • formulations are particularly suitable as active ingredients for supporting the skin functions in dry skin (such as, for example, vitamin C, biotin, carnitine, green tea extracts, eucalyptus oil, urea and mineral salts (such as, for example, NaCl, marine minerals). and osmolytes (such as inositol, betaine, quaternary ammonium compounds)).
  • active ingredients for supporting the skin functions in dry skin
  • active ingredients such as, for example, vitamin C, biotin, carnitine, green tea extracts, eucalyptus oil, urea and mineral salts (such as, for example, NaCl, marine minerals).
  • active ingredients which can be used individually or in combination: Ubiquinone. Folic acid, creatine, carnitine and I-soflavone.
  • active ingredients for alleviating irritative skin conditions have proven to be particularly advantageous.
  • agents such as sericosides, various extracts of licorice, licochalcone, especially licochalcone A, silymarin, silyphos, dexpanthenol, inhibitors of prostaglandin metabolism, in particular the cyclooquine xygenase and the leukotriene metabolism, in particular the 5-lipoxygenase, but also the 5-lipoxevase inhibitor protein, FLAP.
  • the abovementioned active substances are furthermore particularly suitable for creating or renewing an (energy) depot and for activating the repair (repair) of different cellular structures, in particular of the DNA.
  • Licochalcones in particular licochalcone A, and dexpanthenol, which can be used individually or in combination, are very particularly advantageous.
  • compositions are also obtained when antioxidants are used as additives or active ingredients.
  • the preparations advantageously contain one or more antioxidants.
  • antioxidants As favorable, but nevertheless optional to be used antioxidants all suitable or common for cosmetic and dermatological applications or conventional antioxidants can be used.
  • water-soluble antioxidants can be used, such as vitamins, eg. As ascorbic acid and its derivatives - in particular ascorbyl palmitate, Na and Mg ascorbyl phosphate and ascorbyl acetate - and rutinic acid and its derivatives, in particular alpha glucosylrutin, quercetin and isoquercetin.
  • vitamins eg. As ascorbic acid and its derivatives - in particular ascorbyl palmitate, Na and Mg ascorbyl phosphate and ascorbyl acetate - and rutinic acid and its derivatives, in particular alpha glucosylrutin, quercetin and isoquercetin.
  • antioxidants are also vitamin E and its derivatives (especially vitamin E acetate), vitamin A and its derivatives (especially vitamin A palmitate) and carnosine, butylhydroxytoluene, butylated hydroxyanisole, beta-alanine and carotenoids (especially beta-carotene) and phytoene.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05 to 20 wt .-%, in particular 0.1 to 10 wt .-%, based on the total weight the preparation.
  • Vitamin E acetate 0.1 0.1
  • Vitamin E acetate 0.1 0.1 0.1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une combinaison de substances actives constituée a) d'acide glycyrrhétinique et/ou de glycyrrhizine et b) de dihydroxyacétone ainsi que facultativement c) d'érythrulose.
PCT/EP2008/005614 2007-08-31 2008-07-10 Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives Ceased WO2009030302A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007041472A DE102007041472A1 (de) 2007-08-31 2007-08-31 Wirkstoffkombinationen aus Glycyrrhetinsäure und Dihydroxyaceton und kosmetische oder dermatologische Zubereitungen, diese Wirkstoffkombination enthaltend
DE102007041472.4 2007-08-31

Publications (1)

Publication Number Publication Date
WO2009030302A1 true WO2009030302A1 (fr) 2009-03-12

Family

ID=40010487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/005614 Ceased WO2009030302A1 (fr) 2007-08-31 2008-07-10 Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives

Country Status (2)

Country Link
DE (1) DE102007041472A1 (fr)
WO (1) WO2009030302A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009032244A1 (de) * 2009-07-06 2011-01-13 Beiersdorf Ag Glycyrrhetinsäure enthaltende, parfümierte kosmetische Zubereitung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2612776A1 (fr) * 1987-03-25 1988-09-30 Thorel Jean Procede et composition de bronzage en deux phases
US6451293B1 (en) * 1997-03-05 2002-09-17 Pentapharm Ag Combination of erythrulose and a reducing sugar with self-tanning properties
DE10221811A1 (de) * 2002-05-16 2003-11-27 Beiersdorf Ag Malzextrakt enthaltende kosmetischen Zubereitung
US20060263400A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using skin and/or hair care actives
WO2007101559A1 (fr) * 2006-03-01 2007-09-13 Beiersdorf Ag Utilisation d'acide glycyrrhétique et/ou de glycyrrhizine pour préparer des formulations cosmétiques pour le brunissement de la peau

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959079A1 (de) 1969-11-25 1971-07-08 Stavebni Strojirenstvi A Lehka Foerdervorrichtung fuer rohe Ziegeleierzeugnisse
DE102006009780A1 (de) * 2006-03-01 2007-09-06 Henkel Kgaa Viskose remineralisierende Mund- und Zahnpflege- und -reinigungsmittel
DE102006020382A1 (de) * 2006-04-28 2007-10-31 Henkel Kgaa Schnell trocknende kosmetische Emulsionen zur Roll-on-Applikation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2612776A1 (fr) * 1987-03-25 1988-09-30 Thorel Jean Procede et composition de bronzage en deux phases
US6451293B1 (en) * 1997-03-05 2002-09-17 Pentapharm Ag Combination of erythrulose and a reducing sugar with self-tanning properties
DE10221811A1 (de) * 2002-05-16 2003-11-27 Beiersdorf Ag Malzextrakt enthaltende kosmetischen Zubereitung
US20060263400A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using skin and/or hair care actives
WO2007101559A1 (fr) * 2006-03-01 2007-09-13 Beiersdorf Ag Utilisation d'acide glycyrrhétique et/ou de glycyrrhizine pour préparer des formulations cosmétiques pour le brunissement de la peau

Also Published As

Publication number Publication date
DE102007041472A1 (de) 2009-03-05

Similar Documents

Publication Publication Date Title
EP1996153B1 (fr) Utilisation d'acide glycyrrhétique et/ou de glycyrrhizine pour la préparation de compositions pour le bronzage de la peau
EP1089707A1 (fr) Utilisation de preparations cosmetiques contenant des catechines ou un extrait de the vert, pour produits bronzants
DE10342212A1 (de) Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen Hautalterung
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
EP3658112B1 (fr) Associations de principes actifs comprenant du n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyle)benzamide et un ou plusieurs agents et/ou adjuvants de conservation cosmétiquement ou dermatologiquement acceptables
DE10352367A1 (de) Verwendung von Licochalkon A gegen Rosacea
EP2560666B1 (fr) Combinaisons des agents avec un extrait d' ecorce de magnolia et des agents actifs tensioactifs (polyglaceryl(3)-methylglucosedistearate)
DE10352369A1 (de) Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen postinflammatorische Hyperpigmentierung
EP1834630B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et de la 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phényl}-6-(4-methoxyphenyl)-1,3,5-triazine
EP3644953A1 (fr) Utilisation de n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyl)benzamide pour produire des préparations cosmétiques ou dermatologiques destinées au traitement thérapeutique et/ou prophylactique des symptômes du vieillissement cutané intrinsèque et/ou extrinsèque, ainsi que pour le traitement thérapeutique et prophylactique des effets nocifs des rayons ultraviolets sur la peau
EP1834631B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et des dérivés de glucose ou des ethers de glycérine
DE102007041473A1 (de) Verwendung von Glycyrrhetinsäure und/oder Glycyrrhizin zur Herstellung kosmetischer Zubereitungen zur Bräunung der Haut
WO2009030302A1 (fr) Combinaison de substances actives constituée d'acide glycyrrhétinique et de dihydroxyacétone et préparations cosmétiques ou dermatologiques qui contiennent ces combinaisons de substances actives
WO2009030306A1 (fr) Combinaisons de substances actives à base d'énoxolone et d'érythrulose, et préparations cosmétiques ou dermatologiques contenant ces combinaisons de substances actives
WO2010121676A2 (fr) Utilisation d'acide glycyrrhétinique et/ou de ses dérivés pour produire des compositions cosmétiques ou dermatologiques prévenant les dommages de l'adn de la peau et/ou réparant des dommages déjà subis par l'adn de la peau
EP4065239A1 (fr) Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone
DE102007052534A1 (de) Kosmetische Verwendung von weißem Teeextrakt zur Bräunung der Haut
DE10121067A1 (de) Kombination von Tetrahydrocurcuminoiden oder deren Derivaten mit 3-[4-Hydroxyphenylsulfatester]-2-Aminopropionsäure oder 3-[3-Hydroxyphenylsulfatester]-2-Aminopropionsäure (Tyrosin O-Sulfatester) oder entsprechende Sulfonsäureester oder Phosphatester oder ihre Derivate sowie ihre pflanzlichen und tierischen Extrakte als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zur Haufaufhellung oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE102012215501A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Biphenylamin-Derivaten und Verwendung von einem oder mehreren Biphenylamin-Derivaten zur Herstellung kosmetischer Zubereitungen zur Bräunung der Haut
DE102019218243A1 (de) Wirkstoffkombinationen aus Ubichinol und Kreatin und kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
DE10149007A1 (de) Verwendung von Ascorbinsäure zur Herstellung kosmetischer Zubereitungen zur Bräunung der Haut
DE202006021305U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)- 1,3,5-triazin
DE202006021296U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin
DE202006021302U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)- 1,3,5-triazin
DE202006021297U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08773940

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08773940

Country of ref document: EP

Kind code of ref document: A1